To The Moon

Agilent Technologies reports fiscal third-quarter results after the August 26 close with its shares at a 52-week high. The rally reflects improving instrument demand, higher guidance and expansion into cancer diagnostics. The report must show that growth extends beyond temporary order timing and can survive uneven research funding.

For the fiscal second quarter ended April 30 and reported May 27, revenue increased 10% to $1.83 billion and core revenue rose 6.3%. Non-GAAP EPS reached $1.49, while management raised expected fiscal-2026 EPS to $6.00–$6.10. Agilent’s official second-quarter release provides the results.

The bullish thesis rests on recurring demand surrounding scientific instruments. Agilent sells chromatography, mass-spectrometry and spectroscopy systems used in pharmaceutical development, food testing, chemical analysis and academic research. The installed instruments create demand for consumables, software and services long after the original sale. Those recurring streams can be more stable and profitable than instrument shipments.

Agilent’s planned $950 million acquisition of Biocare Medical adds antibodies and tissue-staining systems used in cancer and infectious-disease diagnostics. It complements Agilent’s Dako pathology business and could expand recurring reagent revenue if integration succeeds. Reuters’ March 9 transaction report explains the strategic rationale.

The bearish case is research cyclicality. Academic laboratories depend on grants, pharmaceutical customers can delay capital purchases and Chinese demand remains exposed to local funding and procurement policy. Instrument sales can also be accelerated into one quarter and then slow. Biocare adds acquisition and integration risk at a moment when investors are already pricing in a recovery.

Agilent will report on August 26, according to its official announcement. The stock gained 1.7% to $159 on August 21 after reaching $160.51 on above-average volume. It has risen from $148.44 in three sessions and sits at a 52-week high. Approximately $152–$155 is initial support, followed by $147–$149; $160–$161 is the immediate breakout level. A sustained move above $161 would be constructive, while failure back below $152 would resemble a false breakout.

Chasing premium sales immediately before earnings is unattractive. If Agilent holds above $150 after results and implied volatility declines, a 30–45-day $140/$135 bull put spread with the short strike near 0.10–0.15 delta would position risk beneath the breakout base. A close below $147 with weaker guidance invalidates the structure. Maximum loss equals the $5 width minus credit.

The evidence leans moderately bullish. Core growth, recurring consumables and raised guidance support the breakout, but the valuation assumes a broad laboratory recovery. The view would be invalidated by instrument orders weakening, fiscal-year guidance falling, Biocare integration problems or the stock closing below $147 while estimates decline. This is personal opinion for education and is not financial advice; it is not an instruction to enter any trade.